FR3071M - Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie. - Google Patents

Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.

Info

Publication number
FR3071M
FR3071M FR951110A FR951110A FR3071M FR 3071 M FR3071 M FR 3071M FR 951110 A FR951110 A FR 951110A FR 951110 A FR951110 A FR 951110A FR 3071 M FR3071 M FR 3071M
Authority
FR
France
Prior art keywords
gastroenterology
usable
pancreatic proteases
new pancreatic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR951110A
Other languages
English (en)
Inventor
Jose Uriel
Stratis Avrameas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR951110A priority Critical patent/FR3071M/fr
Priority to US404615A priority patent/US3357894A/en
Application granted granted Critical
Publication of FR3071M publication Critical patent/FR3071M/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/816—Enzyme separation or purification by solubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
FR951110A 1963-10-18 1963-10-18 Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie. Expired FR3071M (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR951110A FR3071M (fr) 1963-10-18 1963-10-18 Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.
US404615A US3357894A (en) 1963-10-18 1964-10-19 Proteolytic enzymes of pig pancreas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR951110A FR3071M (fr) 1963-10-18 1963-10-18 Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.

Publications (1)

Publication Number Publication Date
FR3071M true FR3071M (fr) 1965-01-18

Family

ID=8814721

Family Applications (1)

Application Number Title Priority Date Filing Date
FR951110A Expired FR3071M (fr) 1963-10-18 1963-10-18 Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.

Country Status (2)

Country Link
US (1) US3357894A (fr)
FR (1) FR3071M (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190129B (en) * 1983-07-11 1986-08-28 Reanal Finomvegyszergyar,Hu Process for the isolation of carboxypeptidase b enzyme from mammal pancreas
SE454566B (sv) * 1984-04-24 1988-05-16 Lars G I Hellgren Farmaceutisk komposition innehallande en verksam mengd av vattenlosliga proteinaser som extraherats fran ett vattenlevande djur valt av ordningen euphausiaceae eller slektet mallotus
US5151358A (en) * 1989-06-13 1992-09-29 Genencor International, Inc. Processes for the recovery of naturally produced chymosin
US5139943A (en) * 1989-06-13 1992-08-18 Genencor International, Inc. Processes for the recovery of microbially produced chymosin
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (fr) 2008-07-01 2010-01-07 Curemark, Llc Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
ES2668909T3 (es) * 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571126A (en) * 1943-06-04 1951-10-16 Novo Terapeutisk Labor As Hot aqueous extraction of enzymes from insulin-free pancreas
US2803585A (en) * 1946-10-23 1957-08-20 Novo Terapeutisk Labor As Method of recovering broteolytic pancreas enzymes from mammalian pancreas glands subsequent to insulin removal
US2573099A (en) * 1946-10-23 1951-10-30 Novo Terapeutisk Labor As Method of recovering proteolytic enzymes from mammalian pancreas glands with urea

Also Published As

Publication number Publication date
US3357894A (en) 1967-12-12

Similar Documents

Publication Publication Date Title
FR3071M (fr) Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.
OA00788A (fr) Nouvelles compositions thermoplastiques.
FR2770M (fr) Nouvelles dihalogéno-amino-benzylamines.
DK115369B (da) Flydeleje.
DK107174C (da) Formsten, især betonformsten.
DK105902C (da) Metalbor.
FR2669M (fr) Nouvelles 1,2,4-triazolones-(5).
BE604839A (fr) Nouvelles substances vaso-dilatatrices.
NL150287B (nl) Synchrone demodulator.
FR1522M (fr) Nouvelles diphényléthylamines substituées.
FR96189E (fr) Nouvelles résines thermostables.
FR3259M (fr) Nouvelles compositions hypoglycémiantes.
FR3110M (fr) Nouvelles benzamides.
FR3046M (fr) Nouvelles phényléthanolamines.
FR3308M (fr) Nouvelles pipérazines utilisables en thérapeutique, notamment comme agents anti-inflammatoires.
NL139859B (nl) Stelsel voor gecodeerde berichtenoverdracht.
FR1545M (fr) 11-oxygéno-progestérone-3,20-dioximes.
OA03202A (fr) Nouvelles N-Alcoxyalcoylène-N-Alcoyl urées.
DK113507B (da) Kontaktur.
FR3325M (fr) Nouvelles 2-alcoyl-4-pyridine-aldéhyde-thiosemicarbazones.
BE642025A (fr) Nouvelles indolylalcoylguanidines.
FR3590M (fr) Alpha-(dialcoylamino) trifluorométhylpropiophénones.
DK113039B (da) Stald.
FR2582M (fr) Nouvelles phényl-5 monocycloalcoylamino-2 oxazolinones-4.
FR3864M (fr) Nouvelles pipérazines utilisables en thérapeutique, notamment comme agents hypotenseurs.